Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Lundbeck
|
| gptkbp:acquisitionYear |
2018
|
| gptkbp:developedDrug |
Fasudil
Foliglurax |
| gptkbp:focus |
gptkb:Parkinson's_disease
neurological disorders |
| gptkbp:foundedIn |
2012
|
| gptkbp:founder |
gptkb:Francois_Conquet
|
| gptkbp:headquartersLocation |
gptkb:Geneva,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prexton Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:website |
https://www.prextontherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:MVentures
|
| gptkbp:bfsLayer |
8
|